Search Results
483 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law
I clinical trial in humans, ANAVEX 2-73 was recently chosen by Alzheimer’s Weekly as the number one most About Alzheimer’s While Alzheimer’s is most common in people over the age of 65, it can strike adults modulation of multiple cellular biochemical signaling pathways. [1] Noted in a recent research article (http Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Alzheimer’s Weekly Names ANAVEX 2-73 the Number One Most Promising Trial Drug in Alzheimer’s Disease
(“Anavex”, AVXL.OB) announced today that ANAVEX 2-73 has been named 2010’s “most promising trial drug The full Alzheimer’s Weekly article is available here: http://www.AlzWeek.com/node/970. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints David Tousley as CFO
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- ANAVEX 2-73: Journal of Psychopharmacology Publishes Anti-Amnesic and Neuroprotective Data
receptor/sigma 1 ligand ANAVEX 2-73, a novel aminotetrahydrofuran derivative”, is available online at http Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free:1-866-
- Dr. Cameron Durrant Named One of PharmaVOICE’s 100 Most Inspiring in the Pharmaceutical Industry
the company’s Executive Chairman, has been named in this year’s “PharmaVOICE 100” as one of the 100 most A link to the online edition is available in the media section. Durrant’s expert profile may be viewed from the media section. About ANAVEX Life Sciences Corp. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs
Exploratory biomarkers, pre- / post- neuronal glucose consumption, and comprehensive psychometric test development to accelerate approval timelines and maximize the value of a pharmaceutical, biologic or medical Local CRAs and regulatory expertise ensure fast study set-up and efficient monitoring. multicenter studies, pharmacodynamic phase I studies, including for biologicals, radiopharmaceuticals, and HTPs Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free:1-866-
- Anavex Reports Animal Study Results as Lead Alzheimer’s Compound Approaches Phase 1 Clinical Trials
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Comments on Failure of Pfizer and Medivation’s Dimebon
(“ANAVEX”) (OTCBB: AVXL) today issued a statement following today’s announcement from Pfizer and Medivation Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Dr. Cameron Durrant Executive Chairman of the Board
Durrant is a medically trained MBA who has a unique entrepreneurial background coupled with major international Most recently, Dr. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer's Disease
We look forward to running a high-quality and cost-effective program as ANAVEX works to confirm its pre-clinical Platform involves the rational design of drug compounds that fulfill specific criteria based on unmet medical therapeutic areas are performed in a 72 highly monitored bed equipped centre, which is specifically dedicated For further Information: ANAVEX Research & Business Development Email: info@anavex.com Shareholder & Media
- Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I AD Clinical Trials
Platform involves the rational design of drug compounds that fulfill specific criteria based on unmet medical Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
